Fullintel Daily Digest

RUTGERS CANCER INSTITUTE OF NEW JERSEY IN THE NEWS FEBRUARY 2021

Delivered by Corporate Media Relations

Service Lines

New Brunswick Developer Unveils Plan to Replace Lincoln Annex School. Here's What We Know

Feb 01 | Online Publication| Susan Loyer | Reach: 11,026 | Sentiment : Positive

Home News Tribune - The city planning board will review plans next Monday to build a new elementary school on Jersey Avenue. The new school will replace Lincoln Annex School which will be demolished to make way for the 11-story, 519,000-square-foot Rutgers Cancer Institute of New Jersey Pavilion. Read More

2021 Emerging Scholars: Dr. Adana A.M. Llanos

Feb 02 | Online Publication| Lois Elfman | Reach: 1,942 | Sentiment : Neutral

Diverse - Dr. Adana A.M. Llanos focuses her research on understanding and addressing inequities in cancer outcomes for underserved populations. Llanos is a molecular cancer epidemiologist who engages in transdisciplinary and collaborative studies that examine molecular and sociobiologic mechanisms that contribute to increased cancer incidence and mortality. Focusing on minority and medically underserved populations, she seeks to address and overcome health disparities. Read More

Gynecologic Oncology Leader Named at Rutgers Cancer Institute

Feb 04 | Online Publication | Reach: 1,028,148 | Sentiment : Positive

New Jersey Patch - Expanding its team of highly specialized professionals in the treatment of routine, rare and complex cancers of the female reproductive system, Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital, a RWJBarnabas Health facility, have named James K. Aikins, Jr., MD, FACOG, FACS chief of gynecologic oncology at Rutgers Cancer Institute and chief of gynecologic oncology services at RWJUH, New Jersey's largest academic medical center Read More

Our Role in Beating Cancer Together in New Jersey and Beyond

Feb 04 | Online Publication | Reach: 131 | Sentiment : Positive

HealthNewsDigest.com - At Rutgers Cancer Institute of New Jersey in partnership with RWJBaranabas Health, experts are always working toward the goal of helping individuals fight cancer through onsite research, clinical trials and collaborations with teams locally and across the globe. Read More

Novel Prognostic and Stratification Index Determined Survival Outcomes for Burkitt Lymphoma

Feb 05 | Online Publication| Nichole Tucker | Reach: 458 | Sentiment : Positive

Targeted Oncology - A collaborative effort between Rutgers Cancer Institute of New Jersey and RWJBarnabas Health has led to the discovery and validation of the novel Burkitt Lymphoma International Prognostic Index, a model for prognostication of patients with Burkitt lymphoma. Read More

Mason Scientists and Rutgers Cancer Institute of New Jersey Collaboration Receives U.S. Army’s Breakthrough Award to Better Inform HER2 Breast Cancer Treatment

Feb 08 | Organization | Reach: N/A | Sentiment : Positive

George Mason University - George Mason University’s College of Science announced an exciting $1.33 million collaboration with Rutgers Cancer Institute of New Jersey and Mason’s Center for Applied Proteomics and Molecular Medicine (CAPMM) which taps cancer research diagnostics and treatment strengths within the medical facilities and CAP/CLIA laboratory respectively of the two regional powerhouses. Read More

Also syndicated in:

EurekAlert!, Bioengineer.org and 7thSpace

Syndicated Reach: TM - 118,269

Approval of New CAR-T May Have ‘Immediate Impact’ on Treatment of Large B-Cell Lymphoma

Feb 08 | Online Publication| Drew Amorosi | Reach: 67,206 | Sentiment : Positive

Healio - The uptake of chimeric antigen receptor T-cell therapy has been sluggish despite its tantalizing promise to provide a cure for a large proportion of patients with advanced large B-cell lymphoma. What sets apart lisocabtagene maraleucel — the latest CAR T-cell therapy approved by the FDA for certain types of this disease — are its perceived safety advantages, which may increase access to the potentially life-saving therapy. Read More

Rutgers Professor Is Selected as Emerging Scholar by Higher Education Magazine

Feb 09 | Online Publication| Kithmy Wickramasinghe | Reach: 190 | Sentiment : Positive

Daily Targum - “I engage with the populations I work with in various ways, including serving as a member of community advisory boards and councils that focus on increasing participation of underrepresented minorities in research,” she said. “I engage with these populations by disseminating my research findings to community stakeholders and community audiences.” This includes a presentation in 2019 of her research in cervical cancer screening disparities at the Rutgers Cancer Institute of New Jersey, Llanos said. Read More

Gallbladder & Bile Ducts: Small Organs With Big Responsibilities

Feb 09 | Online Publication | Reach: 1,028,148 | Sentiment : Positive

New Jersey Patch - Advancements in the treatment of these cancers have been primarily in the systemic therapies, such as immunotherapy and target therapy, which are offered to patients at Rutgers Cancer Institute of New Jersey and RWJBarnabass Health. In addition, we are now offering most patients with these disease processes systemic therapy after surgery based on recent clinical trials. These clinical trials for systemic chemotherapy for gallbladder cancer and bile duct cancers are also available at Rutgers Cancer Institute and RWJBarnabas Health. Read More

Breath Holds Protect the Heart During Proton Therapy for Breast Cancer

Feb 09 | Online Publication| Tami Freeman | Reach: N/A | Sentiment : Positive

Physics World - Researchers from the Rutgers Cancer Institute of New Jersey propose that combining the two techniques could reduce cardiac dose further. As previous studies of proton therapy with DIBH are scarce, they have compared photon DIBH with proton DIBH in 10 patients, reporting their findings in the International Journal of Particle Therapy. Read More

New Prognostic Index for Burkitt Lymphoma

Feb 08 | Online Publication| Jeroen Beekwilder | Reach: N/A | Sentiment : Positive

BJH - Burkitt lympohoma is a rare high-grade B-cell lymphoma, which in most cases is studied in small numbers. Definitions of low-risk BL vary, and until now arbitrary cut-off values have been used regarding lactate dehydrogenase. On top of that more than 80 percent of the patients would end up in a further undifferentiated high-risk group. Therefore, there was an urgent need for a practical prognostic index for BL patients. This would help to provide a more adequate patient care, the possibility to compare results from clinical studies and to develop novel targeted treatment approaches. Read More

Salma Jabbour, MD, on the Design of the Ongoing KEYNOTE-799 Study

Feb 10 | Online Publication| Salma K. Jabbour | Reach: 1,890 | Sentiment : Positive

Cancernetwork.com - In an interview with CancerNetwork, Salma Jabbour, MD, chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey, explained the design of the ongoing KEYNOTE-799 study (NCT03631784) which is evaluating pembrolizumab (Keytruda) plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer. Read More

Key Takeaways From the First-in-Human Study of Odronextamab in B-Cell NHL

Feb 10 | Online Publication| Rajat Bannerji | Reach: 458 | Sentiment : Positive

Targeted Oncology - Rajat Bannerji, MD, PhD, of the Rutgers Cancer Institute of New Jersey discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma (NCT0229095). Read More

Surgery Delays for Clinical Renal Cell Carcinoma During COVID-19

Feb 11 | Online Publication | Reach: 1,028,148 | Sentiment : Positive

New Jersey Patch - In a retrospective study, researchers at Rutgers Cancer Institute of New Jersey explored the impact of surgery delays for these patients throughout the United States by utilizing the National Cancer Database to explore outcomes of patients who underwent surgery up to and after three months post diagnosis. Read More

Also syndicated in:

News-Medical.Net, HealthNewsDigest.com and Knowledia

Syndicated Reach: TM - 153,973

2021 Genitourinary Cancers Symposium: Implications of Delaying Surgery for Renal Cell Carcinoma During the COVID-19 Pandemic

Feb 12 | Online Publication | Reach: N/A | Sentiment : Neutral

The ASCO Post - At Rutgers Cancer Institute of New Jersey, surgeries were delayed for 1 to 3 months during the pandemic’s height in New Jersey. Researchers aimed to understand the effect of these surgical delays on patients and their oncologic outcomes. Read More

7 Recent Donations to Healthcare Organizations

Feb 12 | Online Publication| Alia Paavola | Reach: 81,144 | Sentiment : Positive

Becker's Hospital Review - Rutgers Cancer Institute: The cancer institute received an anonymous $25 million donation to support its Cancer Immunology and Metabolism Center of Excellence. Read More

DNA Energy Code: “Survival of the Fittest” Phenomenon Is Only Part of the Evolution Equation

Feb 14 | Online Publication | Reach: 44,390 | Sentiment : Neutral

SciTechDaily - “These revelations matter because they provide entirely new ways of analyzing the human genome and the genome of any living species, the blueprints of life,” said senior author Kenneth J. Breslauer, Linus C. Pauling Distinguished University Professor in the Department of Chemistry and Chemical Biology in the School of Arts and Sciences at Rutgers University–New Brunswick. He is also affiliated with the Rutgers Cancer Institute of New Jersey. Read More

Rutgers Cancer Institute Names New Leader of Gynecologic Oncology

Feb 14 | Online Publication| Sara Karlovitch | Reach: 458 | Sentiment : Positive

Targeted Oncology - The team of oncologic professionals at New Jersey’s only NCI-Designated Comprehensive Cancer Center, Rutgers Cancer Institute, has been expanded to include a new chief of gynecologic oncology. James K. Aikins, MD, FACOGS, FACS, who was selected for the role in early February, will also serve as the chief of gynecologic oncology services for Robert Wood Johnson University Hospital. Read More

Rutgers Names Chief of Gynecologic Oncology

Feb 15 | Online Publication| Erica Carbajal | Reach: 81,144 | Sentiment : Positive

Becker's Hospital Review - New Brunswick, N.J.-based Rutgers Cancer Institute named James Aikins Jr., MD, chief of gynecologic oncology. Dr. Aikins was also named chief of gynecologic oncology services at Robert Wood Johnson University Hospital, the cancer institute's flagship hospital, according to a Feb. 4 announcement. Read More

Know the Signs of Rare but Deadly Gall Bladder, Bile Duct Cancers

Feb 16 | Online Publication| Steven Reinberg | Reach: 7,221 | Sentiment : Positive

Health Day - Most people aren't aware of the signs of gallbladder or bile duct cancer, but the Rutgers Cancer Institute of New Jersey says they should be. The gallbladder is a small organ connected to the liver by bile ducts. Its job is to store bile, which is made by the liver to aid in digestion of fats. Read More

Also syndicated in:

U.S. News & World Report, NewsMax.com, Medical Xpress, Healthfortnight.com, Visionary Blogs and MedicineNet.com

Syndicated Reach: TM - 4,885,088

Faculty at Helm of National Cancer Prevention Organization

Feb 16 | Online Publication| Michelle Edelstein | Reach: 1,028,148 | Sentiment : Positive

New Jersey Patch - Anita Kinney, director of the Center for Cancer Health Equity at Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey, has been elected as the 2021 president-elect of the American Society of Preventative Oncology, a multi-disciplinary society that is committed to serving as an advocate for cancer prevention and control research. In this role, she will serve a two-year term prior to serving as president of the society. Read More

Cancer Prevention: Why, Who, When, Where, How

Feb 15 | Online Publication| Srigowri Kota | Reach: 2,792 | Sentiment : Positive

Oncology Nursing News - While cancer continues to be a leading cause of death globally, oncology nursing is constantly evolving and expanding to meet the emerging needs, including cancer prevention. Read More

Palliative Care Use in Advanced Renal Cell Carcinoma Linked to Socioeconomic Groups

Feb 17 | Online Publication| Jessica Nye | Reach: 4,544 | Sentiment : Neutral

Cancer Therapy Advisor - Researchers from Rutgers Cancer Institute extracted data from 20,122 patients with stage III RCC and 42,014 with stage IV RCC between 2004 and 2014 and evaluated them for palliative care use and demographic characteristics. Read More

Salma Jabbour, MD, on the Results of the Ongoing KEYNOTE-799 Study

Feb 17 | Online Publication| Salma K. Jabbour | Reach: 1,890 | Sentiment : Positive

Cancernetwork.com - In an interview with CancerNetwork®, Salma Jabbour, MD, chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey, discussed the updated results presented at WCLC which reported data with an additional 6 months of follow-up. Read More

Sniffing Out COVID-19, Mounting Hospital Bills and More

Feb 19 | Online Publication| Marie Rosenthal | Reach: N/A | Sentiment : Neutral

Pharmacy Practice News - Patients with hematologic malignancies have demonstrated a potential higher mortality rate due to the virus, according to Andrew M. Evens, DO, MSc, FACP, the associate director for clinical services and director of the Lymphoma Program at Rutgers Cancer Institute, and the medical director of the oncology service line at RWJBarnabas Health, in New Jersey. Read More

Rutgers Cancer Institute of New Jersey Names Gynecologic Oncology Chief

Feb 19 | Online Publication | Reach: 67,206 | Sentiment : Positive

Healio - James K. Aikins Jr., MD, FACOG, FACS, has been appointed chief of gynecologic oncology at Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital. Read More

Precision Medicine When Every Cancer Is Personal Adam Marcus Tedxpeachtree

Feb 22 | Online Publication | Reach: N/A | Sentiment : Positive

Cute766 - Precision medicine for cancer is an approach to deliver the most appropriate treatments based on the characteristics of your cancer. Rutgers Cancer Institute of New Jersey has been at the forefront of such cutting edge science since 2013, even before the launch of a bipartisan national precision medicine initiative in 2015. Read More

Salma Jabbour, MD, on the Impact of the Ongoing KEYNOTE-799 Study

Feb 20 | Online Publication| Salma K. Jabbour | Reach: 1,890 | Sentiment : Positive

Cancernetwork.com - In an interview with CancerNetwork, Salma Jabbour, MD, chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey, discussed the implications of these study findings and how they may impact the treatment of patients with unresectable, locally advanced, stage III NSCLC. Read More

Salma Jabbour, MD, on AEs Observed With Pembrolizumab Plus Concurrent Chemoradiotherapy in Stage III NSCLC

Feb 23 | Online Publication| Salma K. Jabbour | Reach: 1,890 | Sentiment : Neutral

Cancernetwork.com - In an interview with CancerNetwork®, Salma Jabbour, MD, chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey, discussed the adverse events associated with the use of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III NSCLC. Read More

Study Findings Help Explain the Diversity of Cancers in Different Li-Fraumeni Patients

Feb 23 | Online Publication | Reach: 153,649 | Sentiment : Neutral

News-Medical.Net - A recent study from Rutgers Cancer Institute of New Jersey tested this possibility by analyzing tumor formation and p53 mutations in mice from different genetic backgrounds. Observations from this work may further elucidate the diversity of cancers in different Li-Fraumeni patients. Read More

Also syndicated in:

HealthNewsDigest.com

Syndicated Reach: TM - 324

Rutgers Study Finds Little Coronavirus on Cancer Care Facility Surfaces

Feb 22 | Online Publication| Erica Carbajal | Reach: 81,144 | Sentiment : Positive

Becker's Hospital Review - Researchers conducted environmental surface swabbing from outpatient and inpatient oncology clinics and infusion suites across New Brunswick, N.J.-based Rutgers Cancer Institute and Robert Wood Johnson University Hospital for 12 days in June. A total of 204 samples were collected and grouped into the following categories: public areas, staff areas or medical equipment. Of those, 130 samples were collected from two outpatient hematology/oncology clinics, 36 were from surfaces in an inpatient lymphoma/leukemia/CAR-T cell unit and 38 were from an inpatient COVID-19 unit. Read More

Clinical Updates on Relapsed/Refractory Follicular Lymphoma: Where Are We Now and What Is Coming Next?

Feb 22 | Online Publication| Andrew M. Evens | Reach: 840 | Sentiment : Neutral

OncLive - I am Dr Ian Flinn, from the Sarah Cannon research institute in Nashville, Tennessee. Joining me today in this discussion are my colleagues Dr Caron Jacobson, from the Dana-Farber Cancer Institute in Boston, Massachusetts; Dr Andrew Evens, from the Rutgers Cancer Institute of New Jersey; Dr Loretta Nastoupil, from the University of Texas MD Anderson Cancer Center in Houston; and Dr Krish Patel, from the Swedish Cancer Institute in Seattle, Washington. Read More

The Big Ordeal: Understanding and Managing the Psychological Turmoil of Cancer

Feb 22 | Online Publication| Cynthia Hayes | Reach: 252,025 | Sentiment : Neutral

Thrive Global - “The Big Ordeal addresses a critically important need for cancer centers and their patients to better understand the emotional arc of the disease and how to support patients through what is a physically and psychologically challenging experience.” — STEVEN K. LIBUTTI, MD, FACS, Director, Rutgers Cancer Institute of New Jersey; Senior Vice President, Oncology Services, RWJBarnabas Health; Vice Chancellor Cancer Program, Rutgers Biomedical and Health Sciences. Read More

Also syndicated in:

Greenleaf Book Group

Syndicated Reach: TM - N/A

Theralink Technologies Moves Closer Toward Changing the Standard of Care for All Women Newly Diagnosed with HER2+ Breast Cancer

Feb 22 | Online Publication | Reach: 2,183,342 | Sentiment : Positive

Yahoo! Finance - In a recent announcement by Rutgers Cancer Institute of New Jersey and the Center for Applied Proteomics and Molecular Medicine at George Mason University, Theralink Technologies, was named commercial provider of its patented Reverse Phase Protein Array technology for breast cancer patients, if the proposed study has a positive outcome. Read More

Also syndicated in:

Morningstar.com, MarketScreener.com, BioSpace, WFMZ-TV Online, Crwe World, Le Lezard.com, StreetInsider.com and GuruFocus

Syndicated Reach: TM - 710,434

Theralink Partners With George Mason, Rutgers Cancer Institute on Breast Cancer Test

Feb 22 | Online Publication | Reach: 8,711 | Sentiment : Positive

GenomeWeb - Theralink Technologies said on Monday that it is working with George Mason University and the Rutgers Cancer Institute of New Jersey to commercialize an assay that can guide treatment of HER2 positive breast cancer patients. Read More

Also syndicated in:

360Dx and Precision Oncology News

Syndicated Reach: TM - 1,562

Shedding Light on the Forgotten Cancer

Feb 23 | Online Publication | Reach: 1,028,148 | Sentiment : Positive

New Jersey Patch - Currently, Rutgers Cancer Institute experts in the Sarcoma Program are involved in various precision medicine initiatives for sarcomas focusing on personalized treatment for metastatic disease as well as early detection. Clinical trials for sarcomas are also currently being conducted, focusing on both targeted therapy and immunotherapy for treatment of the disease. Read More

Also syndicated in:

sciencenewsnet.in

Syndicated Reach: TM - N/A

Cancer Immunology Center of Excellence Looks to Future Cures, Treatment

Feb 23 | Online Publication | Reach: N/A | Sentiment : Positive

xlete.com - Pretty much each of us has been impacted by cancer at some level, whether personally or when a family member is stricken–or both. Because of this, a cure and treatments are constantly being sought at the Rutgers Cancer Institute of New Jersey’s Cancer Immunology and Metabolism Center of Excellence. Read More

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

Feb 24 | Online Publication| Salma K. Jabbour | Reach: 1,890 | Sentiment : Neutral

Cancernetwork.com - In an interview with CancerNetwork®, Salma Jabbour, MD, chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey, explained how the results of the ongoing study may guide testing moving forward. Read More

In Case You Missed It: Brief Highlights From ASH 2020

Feb 25 | Online Publication| Alice Goodman | Reach: N/A | Sentiment : Neutral

The ASCO Post - “Odronextamab is a novel CD20 × CD3 bispecific antibody that is an off-the-shelf, primarily outpatient treatment option for patients with relapsed or refractory B-cell NHL. In this first-in-human phase I trial, odronextamab has demonstrated compelling antitumor activity, including durable complete responses in heavily pretreated patients with follicular lymphoma and [DLBCL],” said lead author Rajat Bannerji, MD, PhD, Chief of Hematologic Malignancies at Rutgers Cancer Institute of New Jersey. Read More

CURE’s Clinical Trial Corner: February 2021

Feb 25 | Online Publication| Ryan McDonald | Reach: 1,202 | Sentiment : Positive

CURE Magazine - Rutgers Cancer Institute of New Jersey has treated its first patient with upper tract urothelial cancer with a recently approved treatment option. Read More

Surface Testing for SARS-CoV-2 in Hematology, Oncology Settings Finds Negligible Detection

Feb 25 | Online Publication| Aislinn Antrim | Reach: 26,729 | Sentiment : Positive

Pharmacy Times - Researchers from Rutgers Cancer Institute of New Jersey found extremely low levels of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology spaces, suggesting effective sanitation protocols may already be in place. Read More

Expert Explains Why He Uses BV Plus AVD Instead of BEACOPP in Hodgkin Lymphoma

Feb 27 | Online Publication| Andrew M. Evens | Reach: 458 | Sentiment : Positive

Targeted Oncology - During a Targeted Oncology Case-Based Roundtable, Andrew M. Evens, DO, MSc, an associate director of Clinical Services and director of the Lymphoma Program at Rutgers Cancer Institute of New Jersey, as well as the medical director of Oncology Service Line at RWJBarnabas Health in New Brunswick, NJ, discussed testing and treatment for a 22-year-old patient with Hodgkin lymphoma. Read More

De-Escalated IMRT Regimen Shows Promise in HPV-Associated Oropharyngeal Carcinoma

Feb 26 | Online Publication| Jennifer Southall | Reach: 67,206 | Sentiment : Neutral

Healio - The wide landscape of seemingly promising treatment options for HPV-related oropharyngeal squamous cell carcinoma somewhat mirrors that for low-risk prostate cancer and makes the decision-making process incredibly confusing and difficult, Anupama Chundury, MD, and Sung Kim, MD, radiation oncologists at Rutgers Cancer Institute of New Jersey at University Hospital, wrote in an accompanying editorial. Read More

A New Weapon in the Fight Against Cancer: Your Computer

Feb 26 | Online Publication | Reach: 324 | Sentiment : Neutral

HealthNewsDigest.com - COVID-related restrictions may have disrupted many things in our lives, but the virtual world of science has no such limitations. Rutgers Cancer Institute of New Jersey’s Community Cancer Action Board and the Office of Community Outreach and Engagement together launched a Citizen Scientist Program, a unique opportunity that enables scientists and members of the public to unite towards a common goal— to make advancements in cancer research. Read More

Recommended by Fullintel Analysts

You are currently subscribed as info@fullintel.com. For further assistance, please contact Customer Service at support@fullintel.com

Unsubscribe | Privacy Policy